Research location

Dudley

England, United Kingdom

Published trials9

Site observations9

Linked trials published9

Page1 / 1

Research activity in Dudley

England, United Kingdom

CureCurrent currently publishes aggregate city-level research activity for this location: 9 trials and 9 site observations.

The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.

Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.

Trials with sites in Dudley

9 linked trials · page 1 of 1

A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)NCT05093933 · 2021-11-02 · 1 site observation

A Study of Baricitinib (LY3009104) in Participants With Rheumatoid ArthritisNCT03915964 · 2019-04-25 · 1 site observation

Trial of Perioperative Endocrine Therapy - Individualising CareNCT02338310 · 2008-09-01 · 1 site observation

ACTIVE_NOT_RECRUITING

Dalteparin in Preventing Blood Clots in Patients With Lung CancerNCT00519805 · 2007-08-01 · 1 site observation

Combination Chemotherapy in Treating Patients With Early Stage Breast Cancer That Has Been Removed By SurgeryNCT00301925 · 2005-12-16 · 1 site observation

Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug EfficacyNCT00268476 · 2005-07-08 · 1 site observation

ACTIVE_NOT_RECRUITING

Goserelin in Preventing Early Menopause in Premenopausal Women Undergoing Chemotherapy for Stage I, Stage II, or Stage III Breast CancerNCT00427245 · 2004-08-01 · 1 site observation

Single-Dose Local Radiation Therapy Compared With Ibandronate in Treating Patients With Localized Metastatic Bone PainNCT00082927 · 2003-04-01 · 1 site observation

Study of Blood and Tumor Samples From Men With an Inherited Risk of Prostate CancerNCT00959023 · 1993-06-01 · 1 site observation

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.